In various metastatic cancers, patients treated with PI3K/AKT/mTOR pathway inhibitors in combination with other treatments (ET, anti-HER2 therapy, or chemotherapy) had a longer time to progression compared to patients without PIK3CA mutations [26]. Here, ERBB2 is linked to metastatic malignant neoplasm.